Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with Crohn's disease.

Strategies to improve the immunosuppressive properties of human mesenchymal stem cells. Stem Cell Res Ther (2015) 0.80

LL-37 boosts immunosuppressive function of placenta-derived mesenchymal stromal cells. Stem Cell Res Ther (2016) 0.75

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood (2002) 9.40

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 6.02

Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12

Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut (2009) 4.06

Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81

Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood (2005) 3.37

Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med (2011) 3.11

Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut (2010) 3.09

Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol (2007) 2.65

Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis (2010) 2.64

Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells (2006) 1.63

Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant (2011) 1.33

Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27

Macrophages modulate the viability and growth of human mesenchymal stem cells. J Cell Biochem (2013) 1.09

Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut (2011) 1.07

Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc (2009) 0.96

Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. Br J Clin Pharmacol (2012) 0.87

The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. Cytotherapy (2010) 0.86

Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media. Stem Cell Res Ther (2014) 0.80